IL313677A - Fitusiran for use in improving patient-reported outcome in hemophilia patients - Google Patents

Fitusiran for use in improving patient-reported outcome in hemophilia patients

Info

Publication number
IL313677A
IL313677A IL313677A IL31367724A IL313677A IL 313677 A IL313677 A IL 313677A IL 313677 A IL313677 A IL 313677A IL 31367724 A IL31367724 A IL 31367724A IL 313677 A IL313677 A IL 313677A
Authority
IL
Israel
Prior art keywords
phytosiran
hemophilia
patients
improving outcomes
outcomes reported
Prior art date
Application number
IL313677A
Other languages
English (en)
Hebrew (he)
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of IL313677A publication Critical patent/IL313677A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL313677A 2021-12-22 2022-12-22 Fitusiran for use in improving patient-reported outcome in hemophilia patients IL313677A (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163293070P 2021-12-22 2021-12-22
US202263305550P 2022-02-01 2022-02-01
US202263335535P 2022-04-27 2022-04-27
US202263359717P 2022-07-08 2022-07-08
US202263382223P 2022-11-03 2022-11-03
US202263386489P 2022-12-07 2022-12-07
PCT/US2022/082213 WO2023122713A1 (en) 2021-12-22 2022-12-22 Fitusiran for use in improving patient-reported outcome in hemophilia patients

Publications (1)

Publication Number Publication Date
IL313677A true IL313677A (en) 2024-08-01

Family

ID=85227438

Family Applications (1)

Application Number Title Priority Date Filing Date
IL313677A IL313677A (en) 2021-12-22 2022-12-22 Fitusiran for use in improving patient-reported outcome in hemophilia patients

Country Status (10)

Country Link
US (1) US20250064842A1 (cg-RX-API-DMAC7.html)
EP (1) EP4452280A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025500412A (cg-RX-API-DMAC7.html)
KR (1) KR20240138572A (cg-RX-API-DMAC7.html)
AU (1) AU2022419588A1 (cg-RX-API-DMAC7.html)
CA (1) CA3243297A1 (cg-RX-API-DMAC7.html)
IL (1) IL313677A (cg-RX-API-DMAC7.html)
MX (1) MX2024007894A (cg-RX-API-DMAC7.html)
TW (1) TW202342065A (cg-RX-API-DMAC7.html)
WO (1) WO2023122713A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025171279A1 (en) * 2024-02-09 2025-08-14 Genzyme Corporation Treatment of hemophilia with fitusiran

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9127274B2 (en) 2012-04-26 2015-09-08 Alnylam Pharmaceuticals, Inc. Serpinc1 iRNA compositions and methods of use thereof
IL308717A (en) 2015-12-07 2024-01-01 Genzyme Corp Methods and compositions for treating a serpinc1-associated disorder
JP2020530442A (ja) 2017-07-10 2020-10-22 ジェンザイム・コーポレーション 血友病を有する対象の出血事象を処置するための方法および組成物
WO2022120291A1 (en) * 2020-12-06 2022-06-09 Genzyme Corporation Treatment of hemophilia with fitusiran

Also Published As

Publication number Publication date
MX2024007894A (es) 2024-08-20
JP2025500412A (ja) 2025-01-09
KR20240138572A (ko) 2024-09-20
AU2022419588A1 (en) 2024-08-01
WO2023122713A1 (en) 2023-06-29
US20250064842A1 (en) 2025-02-27
CA3243297A1 (en) 2023-06-29
TW202342065A (zh) 2023-11-01
EP4452280A1 (en) 2024-10-30

Similar Documents

Publication Publication Date Title
CY20152200002T2 (el) Μονοθεραπεια (psi-7977) ή συνδυαστικη θεραπεια με daas για χρηση στην αντιμετωπιση του hcv
DK2912074T3 (da) Dermal injicerbar steril sammensætning
BR302013006822S1 (pt) Configuração aplicada em curativo médico.
DK3909966T3 (da) 19-nor c3,3-disubstitueret c21-n-pyrazolylsteroid til brug i behandling
IL234028B (en) Catheter for the treatment of atrial flutter having single action dual deflection mechanism
PL2766040T3 (pl) Pertuzumab, trastuzumab, docetaksel i karboplatyna w leczeniu wczesnego stadium raka piersi
IT1400425B1 (it) Modified snrnas for use in therapy.
EP2929436A4 (en) STOP CRITERIA FOR HISTORIZED ITERATIVE ERROR CORRECTION
BRDI7104784S (pt) Configuração aplicada em instrumento médico
BRDI7106721S (pt) Configuração aplicada em instrumento médico
BR112015004370A2 (pt) composição esterilizada, processo de fabricação da mesma, utilização da mesma, e, kit
BRDI7103743S (pt) Configuração aplicada em instrumento médico
BRDI7104782S (pt) Configuração aplicada em instrumento médico
BR302012001336S1 (pt) Configuração aplicada em instrumento médico
BRDI7106720S (pt) Configuração aplicada em instrumento médico
BRDI7104785S (pt) Configuração aplicada em instrumento médico
IL289787A (en) Antibody combinations for treatment of cancer in specific patients
UY34043A (es) Isoxazolinas como agentes terapéuticos
EA201590503A1 (ru) Альфа-1-микроглобулин для применения в лечении заболеваний, связанных с митохондриями
CO6920289A2 (es) Composición farmacéutica oftalmológica tópica que contiene regorafenib.
BR302012003127S1 (pt) Configuração aplicada em instrumento médico
EP2773419A4 (en) IMPLANTABLE MEDICAL PASSIVE ELECTRODE
BRDI7104906S (pt) Configuração aplicada em instrumento médico
MX374220B (es) Nepentesina para usarse en el tratamiento de la intolerancia al gluten y padecimientos relacionados.
HUE043419T2 (hu) Vegyületek remielinizációs blokk kezelésére HERV-W borítékfehérje expresszióval járó betegségekben